Novartis Proactively Halts Global Distribution of Generic Zantac Amid NDMA Contamination Concerns

Compiled | newborn

Recently, the issue of NDMA impurities has once again stirred up considerable controversy in the pharmaceutical industry. The trigger was the detection of NDMA in drugs such as Sanofi’s Zantac (ranitidine). However, the FDA’s response has been markedly different, standing in stark contrast to the stringent sanctions imposed on Huahai Pharmaceutical. Nevertheless, some U.S. online pharmacy platforms have filed petitions calling for the FDA to recall Zantac and other related medications. (See details:Same Impurities, Different Fates!Sanofi’s Zantac and Other Drugs Containing NDMA Not Recalled: A US Online Pharmacy Files a Petition）

Before the FDA and other pharmaceutical companies took action, one company had already taken the initiative by immediately halting global distribution of its generic version of Zantac. That company was Novartis. Notably, not long ago, Novartis was embroiled in a data manipulation scandal involving its SMA gene therapy, Zolgensma. The company’s proactive stance this time is highly commendable.

The FDA deemed it unnecessary to require manufacturers to recall their generic versions of the antacid Zantac during the investigation, whereas Health Canada and certain European regulatory agencies adopted a more aggressive stance by mandating that manufacturers halt distribution. Unlike a recall, this measure allows existing inventory in pharmacies to remain available for sale.

On Wednesday, Novartis announced that it is halting the global distribution of its generic version of Zantac. Eric Althoff, Head of Global Media Relations, stated in an email: “Pending further clarification, our preventive sales ban on all Sandoz ranitidine-containing products across all markets will remain in effect, including capsule formulations sold in the U.S. market.”

Sanofi is currently selling the brand-name Zantac OTC, with the company taking a relatively passive approach at present. A spokesperson stated that there are currently “no plans to halt the distribution or production of Zantac or other ranitidine products outside Canada.” The spokesperson added that Sanofi is working closely with the U.S. Food and Drug Administration (FDA), noting that preliminary FDA testing indicated that NDMA levels in Zantac were barely above those found in common food items.

Last week, the FDA issued a public notice regarding the detection of NDMA in ranitidine medications and announced that it is conducting an investigation to determine the source of the contaminated ingredient and the associated risk levels in these drugs. To date, the FDA has stated that the risk to consumers appears to be low. However, this assertion has not been universally accepted. Valisure, a U.S. online pharmacy, has submitted a citizen petition urging the FDA to recall all ranitidine products and to establish standards consistent with those applied to angiotensin II receptor blockers (ARBs) containing NDMA.

Reference Source: Novartis Doesn't Wait for FDA Investigation and Halts Distribution of Its Generic Zantac